OBJECTIVES Suboptimal blood pressure (BP) control is commonly observed in patients receiving antihypertensive agents, but it remains unknown the relationship between uncontrolled BP and early impairment of left atria (LA) function.
Parameters
Controls HT gp HTgp1 HTgp2
HTgp1 vs.
HTgp2
Systolic CONCLUSIONS Hypertensive patients are associated with early impairment of LA myocardial function detected by TDI and free strain speckle tracking. Furthermore, early impairment of LA function could be attribute to suboptimal BP control as these patients are associated with reduced V Ea and S Ea , therefore, more intensive therapy should be considered.
GW26-e1577
Serum Cystatin C as a Potential Predictor for the Progression of Prehypertension-to-hypertension OBJECTIVES Cystatin C (CysC) is considered to be a risk factor of cardiovascular diseases. However, the association between CysC and the progression of prehypertension-to-hypertension is not evaluated before.
METHODS A total of 463 consecutive patients with prehypertension were enrolled. Serum CysC levels at baseline were measured via an immunoturbidimetric technique. Then, all subjects underwent a median three-year follow-up. The primary endpoint was the progression of prehypertension-to-hypertension diagnosed by upper-arm blood pressure monitor. A proportional hazard regression analysis was implemented to model the interval-censored progression-free survival time data. Receiver operating characteristic curves (ROC) and multivariate logistic regression analysis were used to evaluate the predictive value of serum CysC. .001] was an independent predictor for the progression of prehypertension-to-hypertension. ROC analysis showed that the AUC of serum CysC for predicting the progression of prehypertension-tohypertension was 0.824 (95%CI 0.734-0.912), with an optimum cut-off of 1.18mg/dl.
RESULTS
CONCLUSIONS Serum CysC might serve as a potential predictor for the progression of prehypertension-to-hypertension.
GW26-e2299
Lifestyle OBJECTIVES Last year we reported that lifestyle modification in patients with stage 1 hypertension could achieve goal of blood pressure. Additional perindopril therapy could achieve lower blood pressure with lower sensitivity C-reactive protein (hsCRP) and macrophage inhibitory factor (MIF) serum levels. But the difference was slight which might be associated with the short period of follow-up (8 weeks). In order to further define the anti-inflammatory effect of hypotenser treatment on stage 1 hypertension patients, we extended the follow-up period to 1 year and monitored the above indexes.
METHODS 86 patients were enrolled into the study after signing informed consent and they were divided into lifestyle modification group (average age 54.1AE7.2yrs) and perindopril therapy group (average age 56.1AE6.7yrs) by matched pair design. Perindopril therapy was added in the latter group while both groups received lifestyle modification. Peripheral serum was collected at the time of enrollment, week 4, week 8, week 12, week 24, week 36 and week 48. ELISA was applied to determine the serum level of hsCRP and MIF. Patients' financial expense on medication was recorded. Data was finally analyzed by SPSS 19.0.
RESULTS
In the last year's submission we showed that additional perindopril therapy led to better blood pressure control, with lower hsCRP and MIF but the difference was slight at week 4 and 8. After 1 year's follow-up there were 8 lost cases (9.3%, 5 cases in lifestyle modification group v.s. 3 cases in perindopril therapy group) (P>0.05).
There was still no significant difference of blood pressure between two groups at week 12 and week 24. At week 36 and week 48 perindopril therapy group showed lower systolic blood pressure ( CONCLUSIONS Extended follow-up showed that lifestyle modification still improved blood pressure control and lowered inflammatory markers. Additional perindopril therapy could help to further alleviate inflammation status with the price of increased adverse events and financial expense. Personalized therapy was still advised in those hypertensive patients with high risk factors and high load of inflammation.
